Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Chiron deal

Quarterly product sales grew to $50.1 million from $28.6 million, due to increased product sales from the Chiron Vision ophthalmic business, and $10.5 million in initial shipments of Betaseron (Interferon beta-1b)

Read the full 319 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE